Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;164(2):242-252.
doi: 10.1111/imm.13378. Epub 2021 Jul 8.

Endocannabinoids in immune regulation and immunopathologies

Affiliations
Review

Endocannabinoids in immune regulation and immunopathologies

Oindrila Rahaman et al. Immunology. 2021 Oct.

Abstract

Endocannabinoids are key bioactive components of the endocannabinoid system, and the profound influence of endocannabinoids on the modulation of the immune system is being increasingly appreciated. The knowledge of endocannabinoid-immune cell crosstalk will pave the way to therapeutic implications of modulators of this pathway in autoimmune and chronic inflammatory disorders. Endocannabinoids seem to exert both anti-inflammatory and pro-inflammatory effects in specific contexts, based on specific receptor engagement and the downstream signalling pathways involved. In this review, we summarized the biosynthesis, signalling and degradation of two well-studied endocannabinoids-anandamide and 2-arachidonylglycerol in immune cells. Then, we discussed the effects of these two endocannabinoids on the functioning of major innate and adaptive immune cells, along with the choice of receptors employed in such interactions. Finally, we outline our current knowledge on the involvement of anandamide and 2-arachidonylglycerol in context of inflammation, allergies, autoimmunity and metabolic disorders.

Keywords: 2-AG; CB2; anandamide; autoimmunity; endocannabinoids; immune cells; inflammation; metabolic disorder.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

FIGURE 1
FIGURE 1
Biosynthesis, uptake and catabolism of the endocannabinoids—anandamide (AEA) and 2‐AG. Lower panel shows synthesis of endocannabinoids in immune cells in response to different stimuli and through different pathways for different endocannabinoids. Middle panel shows the binding and signalling of endocannabinoids thus released in the responding cells mostly through the cannabinoid receptors CB1R and CB2R, which are G protein‐coupled receptors. Top panel shows the hydrolysis or oxygenation of endocannabinoids in the cytoplasm of responding cells, thus terminating the direct effect of the endocannabinoids
FIGURE 2
FIGURE 2
Effects of anandamide and 2‐AG on various immune cells in a nutshell. Both anandamide and 2‐AG exert immunomodulatory roles on major immune cells such as T cells, B cells, natural killer cells, neutrophils, monocytes, macrophages, microglia, eosinophils, classical dendritic cells (cDC) and plasmacytoid dendritic cells (pDCs) as schematically represented. The choice of receptors on each cell varies depending on the specific effect of the endocannabinoid. CB1R, CB2R, GPR55, BLT1 and COX‐2 are already reported receptors for some of the effects (as shown over the arrowhead), while the receptors involved in the other effects remain to be identified

References

    1. Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79:516–25. - PMC - PubMed
    1. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646–7.
    1. Howlett AC. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci. 1984;35:1803–10. - PubMed
    1. Howlett AC. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol. 1985;27:429–36. - PubMed
    1. Howlett AC, Qualy JM, Khachatrian LL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol. 1986;29:307–13. - PubMed

Publication types

LinkOut - more resources